Weyerhaeuser Company v. Richard Pritt

CourtIntermediate Court of Appeals of West Virginia
DecidedApril 29, 2025
Docket24-ica-355
StatusPublished

This text of Weyerhaeuser Company v. Richard Pritt (Weyerhaeuser Company v. Richard Pritt) is published on Counsel Stack Legal Research, covering Intermediate Court of Appeals of West Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Weyerhaeuser Company v. Richard Pritt, (W. Va. Ct. App. 2025).

Opinion

IN THE INTERMEDIATE COURT OF APPEALS OF WEST VIRGINIA

WEYERHAEUSER COMPANY, FILED Employer Below, Petitioner April 29, 2025 ASHLEY N. DEEM, CHIEF DEPUTY CLERK v.) No. 24-ICA-355 (JCN: 2023015296) INTERMEDIATE COURT OF APPEALS OF WEST VIRGINIA

RICHARD PRITT, Claimant Below, Respondent

MEMORANDUM DECISION

Petitioner Weyerhaeuser Company (“WC”) appeals the August 8, 2024, order of the Workers’ Compensation Board of Review (“Board”). Respondent Richard Pritt filed a response.1 WC filed a reply. The issue on appeal is whether the Board erred in reversing the claim administrator’s order, which rejected the claim.

This Court has jurisdiction over this appeal pursuant to West Virginia Code § 51- 11-4 (2024). After considering the parties’ arguments, the record on appeal, and the applicable law, this Court finds no substantial question of law and no prejudicial error. For these reasons, a memorandum decision affirming the Board’s order is appropriate under Rule 21 of the Rules of Appellate Procedure.

Mr. Pritt filed an occupational disease claim, and indicated that his date of last exposure was July 20, 2022.2 Prior to filing the claim application, on July 23, 2020, Mr. Pritt received an email from Kevin Cochran,3 indicating that the MDI levels were tested after receiving reports of high levels, and the levels were found to be “in line with what [they] generally see.” On July 27, 2020, Mr. Pritt had an email exchange with Steve Cutlip regarding his exposure to methylene diphenyl diisocyanate (“MDI”) and formaldehyde in the week prior.4 Mr. Pritt was informed that the respirator filter that he used while working

1 WC is represented by Richard W. Gallagher, Esq., and Mark J. Grigoraci, Esq. Mr. Pritt is represented by Lucas R. Tanner, Esq. 2 This claim application was not included in the record below, but this information was noted by the Board. It is unclear when the claim application was filed. 3 It appears that Mr. Cochran was employed by WC at the time of the email exchange, but his title and responsibilities within the company are not made clear from the record. 4 It appears that Mr. Cutlip was employed by WC at the time of the email exchange, but his title and responsibilities within the company are not made clear from the record. 1 with the chemicals was not approved for exposure to those chemicals. Mr. Pritt indicated that post exposure he was shaking all over, he developed burning in his eyes and throat, and weakness in his legs. Mr. Pritt requested that his exposure be documented.

Covestro completed an Industrial Hygiene Evaluation on May 11, 2022, and issued its report on June 9, 2022. Covestro evaluated the WC Sutton OSB facility in Heaters, West Virginia for airborne concentrations of MDI. Forty-two samples were collected during the manufacture of 7/16-inch wall and roof sheathing. All of the samples measured below the American Conference of Governmental Industrial Hygienists Threshold Limit Value - Time Weighted Average of 5 parts per billion (“ppb”) for MDI monomer. The results were also below the adjusted Threshold Limit Value of 3.3 ppb for a 12-hour work shift.

On May 2, 2023, Mr. Pritt was evaluated by Syam Stoll, M.D. Mr. Pritt reported several significant occupational exposure incidents including one that occurred in 2021, when WC was having difficulty obtaining respirator cartridges. Mr. Pritt stated that the new storeroom employee mistakenly ordered respirator cartridges that did not protect against MDI and formaldehyde, and Mr. Pritt had unknowingly used the wrong cartridges while blowing down the press and was exposed to chemicals. Mr. Pritt stated that forty- five minutes after the exposure he began to shake badly and developed burning in his eyes, nose, throat, and chest. Mr. Pritt further reported that he took a reading with a handheld MDI dosimeter following that incident and it showed 60 ppb. Mr. Pritt noted that OSHA’s recommended permissible exposure limit was 5 ppb. Mr. Pritt reported that he had no breathing issues and felt great after being off work for a week in November, but he subsequently began to experience increased chest tightness a day or two after returning to work. Mr. Pritt also reported developing blisters on his skin and scalp when he works. Dr. Stoll opined that Mr. Pritt’s “alleged” occupational disease exposure was based solely upon his subjective complaints; Mr. Pritt’s pulmonary function and radioallergosorbent (“RAST”) testing did not support a direct causal connection to his work duties and the “alleged” occupational disease; objective medical documentation did not support that Mr. Pritt sustained the alleged occupational disease as a result of being exposed in the course of his employment and job duties; Mr. Pritt had no evidence of an occupational disease; and Mr. Pritt’s subjective complaints were due to non-occupational causes.5

Marcus Cervantes, M.D., Mr. Pritt’s treating physician and an environmental and occupational medicine physician, authored a letter dated October 14, 2023. Dr. Cervantes indicated that Mr. Pritt first presented with complaints of wheezing, a dry cough, chest tightness, and dyspnea. Mr. Pritt reported that his symptoms increased in frequency and

5 Dr. Stoll failed to identify any potential nonoccupational causes of Mr. Pritt’s symptoms.

2 nature based upon the amount of time he spent in the workplace. Mr. Pritt noted that his symptoms would lessen or resolve over weekends, vacations, and other extended periods away from work, and then return shortly after he reentered the workplace. Mr. Pritt reported that he did not have a prior history of asthma. Dr. Cervantes opined that the symptoms were classic for work-related asthma and sensitivity and that Mr. Pritt’s initial spirometry findings were consistent with a diagnosis of asthma. Dr. Cervantes noted that MDI is a sensitizing agent that is capable of causing irritant asthma with high dose exposure or chronic, low-level exposures over the course of months or years. Dr. Cervantes opined that, because Mr. Pritt worked for WC for at least twenty years, there was biological plausibility within a reasonable degree of certainty that he could have developed sensitization to either MDI or formaldehyde from his employment.

Dr. Cervantes indicated that although the RAST testing performed for both MDI and formaldehyde was negative, in his clinical experience he found that RAST testing cannot be relied upon for diagnostic purposes. Dr. Cervantes noted that he had seen patients with clear diagnoses of sensitivity and asthma, but who had negative RAST tests. Further, Dr. Cervantes found it plausible that a sensitized worker would have undetectable levels of the offending agent on RAST testing with cessation of exposure. Dr. Cervantes noted that Mr. Pritt reported that he had been moved to the control room since January 2023 where his exposure to MDI and formaldehyde was more sporadic in nature. Thus, Dr. Cervantes opined that Mr. Pritt’s RAST testing was consistent with this reported occupational exposure history.

Dr. Cervantes noted that after Mr. Pritt’s initial spirometry, which showed significant asthma-like bronchial reactivity, Mr. Pritt was removed from the workplace with a plan to repeat spirometry six to eight weeks later. Dr. Cervantes opined that this is a classic pattern for the diagnosis of occupational asthma, as repeat spirometry performed several weeks after withdrawal from the offending agent should show objective improvement in lung function and volumes. Dr. Cervantes further noted that following removal from the workplace, Mr. Pritt’s FEV1/FVC improved to 0.70 and there was also complete resolution of the previously noted bronchial hyperactivity. Dr. Cervantes opined that these findings were consistent with Mr. Pritt’s clinical picture, as occupational asthma from sensitization is a reversible obstruction.

Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Martin v. Randolph County Board of Education
465 S.E.2d 399 (West Virginia Supreme Court, 1995)
In Re Queen
473 S.E.2d 483 (West Virginia Supreme Court, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
Weyerhaeuser Company v. Richard Pritt, Counsel Stack Legal Research, https://law.counselstack.com/opinion/weyerhaeuser-company-v-richard-pritt-wvactapp-2025.